The diabetes epidemic has contributed in the growth of the antidiabetics market the past few years. Since the prevalence of diabetes continues to increase, the market will further expand. While early therapy is dominated by generically available agents, and the later stages by insulin, the number of unmet needs in the diabetes treatment, warrants that novel agents will have a place in the market.

Scope

Country specific event-driven sales forecasts for the period 2007-16 for the US, Japan, France, Germany, Italy, Spain and the UK. Patient potential and prescribing trends overview of the antidiabetics market based on historical sales data and future key events. Profiles of the country and market specific issues which will impact future sales in the market including generic erosion and class switching. Case studies presenting safety issues and the role that novel agents are likely to play in the balance of issues and opportunities in the market

Highlights

Insulin class dominates the market with a 40.9% share of its overall seven major market sales and the US market accounts for 66% of the value of the seven major markets with 13% CAGR 200306. Although insulin, sulfonylureas and biguanides remain the highest selling drug classes (number of units sold) in the antidiabetics market a strong need for new drugs with fewer side effects and better tolerability have created a potential niche for companies to compete for. Patients with Type 2 diabetes who are poorly controlled with metformin and/or sulfonylureas are subjects to second-line therapy with TZDs. For a number of years this class was in dispute due to its safety concerns.

Reasons to Purchase

Quantify future size and scope of the diabetes market and potential for new products Analyze options to expand commercial potential through pursuit of new indications Formulate successful launch strategies in a highly competitive market